ArticleJCO precision oncology2022
Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion-Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?
Article in JCO precision oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Larotrectinib in TRK fusion differentiated thyroid carcinoma: updated trial data.Endocrine-related cancer · 2026Article
- Targeted therapy in thyroid cancer: molecular alterations and clinical management.Frontiers in endocrinology · 2026Review
- Redifferentiation Effect of Larotrectinib forJournal of the Endocrine Society · 2025Article
- Durable Response to Redifferentiation in a Patient With MetastaticJCEM case reports · 2025Article
- Molecular Landscape and Therapeutic Strategies in Pediatric Differentiated Thyroid Carcinoma.Endocrine reviews · 2025Review
- Paediatric Thyroid Carcinoma: The Genetic Revolution and Its Implications for Therapy and Outcomes.Cancers · 2025Review
- Single-Institution Experience of Larotrectinib Therapy for Patients WithJournal of the Endocrine Society · 2024Article
- Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status.Journal of endocrinological investigation · 2024Article
- Neurotrophic-tyrosine receptor kinase gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland.Oncotarget · 2024Article
- Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy.Frontiers in immunology · 2024Review
- The Evolving Genomic Landscape of Pediatric Papillary Thyroid Cancer.Current opinion in endocrine and metabolic research · 2023Article
- Children's Oncology Group's 2023 blueprint for research: Rare tumors.Pediatric blood & cancer · 2023Article
- Kinase inhibitors in thyroid cancers.Endocrine oncology (Bristol, England) · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.